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Conclusion: We conclude that differences exist in baseline, angiographic and
procedural characteristics, and 1-year clinical outcomes between Western-European
and Asian patients undergoing non-urgent PCI. Our results indicate that reports from
worldwide performed studies should include both overall and regional subgroups
outcomes.
TCT-247
Preliminary Data from ABSORB EXTEND: A Report of the 6-month Clinical
Outcomes from the First 200 Patients Enrolled
Alexandre Abizaid1, Antonio L Bartorelli2, Robert Whitbourn3, Lee Clark4, Bernard
Chevalier5, Karine Miquel-Hebert6, Robert J Van Geuns7, Didier Carrie8, Pieter C
Smits9, John A Ormiston10, Robert McGreevy4, Ashok Seth11, Patrick W Serruys7
1Instituto de Cardiologia Dante Pazzanese, Sao Paulo, Brazil; 2Centro Cardiologico
Monzino, IRCCS, University of Milan, Milan, Italy; 3St. Vincent’s Hospital, Fitzroy,
Australia; 4Abbott Vascular, Santa Clara, CA; 5Institut Jacques Cartier, Massy,
France; 6Abbott Vascular, Diegem, Belgium; 7Thoraxcenter, Erasmus Medical
Center, Rotterdam, Netherlands; 8Hopital Rangueil, Toulouse, France; 9Maasstad
Ziekenhuis, Rotterdam, Netherlands; 10Mercy Angiography, Mercy Hospital,
Auckland, New Zealand; 11Escorts Heart Institute and Research Centre, New Delhi,
India
Background: The safety and performance of the ABSORB™ Bioresorbable Vascular
Scaffold (BVS) System (Abbott Vascular, Santa Clara, CA) has been previously
established in 131 patients from Cohort A and Cohort B of the First-in-Man ABSORB
trial. Following this trial, ABSORB EXTEND was initiated as a global continued
access study (outside of the US) to expand experience with the ABSORB BVS to
patients with increased lesion complexity. This includes patients treated for longer
coronary lesions than those in the ABSORB trial using either longer scaffold lengths
or planned overlap of the ABSORB BVS.
Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study
that is planning to enroll up to 1,000 subjects at up to 100 sites. Included are patients
with lesions ≤ 28 mm in length and reference vessel diameter of 2.0 - 3.3 mm (as
assessed by on-line QCA). Treatment of a maximum of two de novo native coronary
artery lesions, each in a different epicardial vessel, is permitted.
Results: Results out to 1 year have been presented in 101 patients from the ABSORB
Cohort B trial. At 6 months, the MACE rate was 5.0% (5/101), with no cardiac death
or scaffold thrombosis reported. These clinical results were sustained out to 12 months
in Cohort B with a MACE rate of 6.9% (7/101) reported at 12 months. Preliminary 6-
month data in the first 200 patients enrolled in ABSORB EXTEND will be available
for the first time in October 2011 and will provide additional data on the safety and
performance of the ABSORB BVS in a larger population of patients, including those
with longer lesions and two-vessel disease. Clinical composites and component end
points will be presented out to 6 months.
Conclusion: Clinical and angiographic outcomes from the First-in-Man ABSORB trial
have demonstrated the safety and efficacy of the ABSORB BVS in lesions ≤ 14 mm.
Preliminary outcomes in 200 patients at 6 months from ABSORB EXTEND will
provide further insight into the mid-term safety and efficacy of the ABSORB BVS in
patients with longer lesions.
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Background: The purpose of our study is to analyze the long-term results of coronary
intervention with DES and EPC-capturing stents, and determine risk factors influencing
long-term adverse coronary events rate after usage of different types of stents.
Methods: 2362 patients were enrolled in the study. 316 patients underwent
percutaneous coronary interventions (PCI) with EPC capturing Genous stent, 2046
patients - with drug (sirolimus) eluting stents. The primary endpoint of the study was
the occurrence of MACE in two groups. The secondary endpoints were the rate of stent
thrombosis, stent restenosis, level of pnflammatory response after discontinuation of
dual antiplathelet therapy. In each group independent predictors of MACE were
determined.
Results: During second year of follow-up the incidence of MACE was 16% in DES
group and 14% - in Genous group. In Genous group more patients requred subsequent
revascularization procedures(12%)compared to DES group(4%).In DES group age,
renal insufficiency, diabetes mellitis,discontinuation of DAPT due to noncardiac
surgery were inedtifed as univariate predicrots. Discontinuation of DAPT was the
independent predictors of MACE in DES group. In Genous group age,diabetes mellitis,
long lesion were univariate predicrots, long lesions became the independent predictors
of MACE.In DES group in diabetic patients there was increase of C-protein level after
discontinuation of dual antiplathelet therapy. Patients after DES implantation and
noncardiac surgery had higher rate of stent thrombosis (18%) rate compared to patients
after Genous stents (0%).
Conclusion: Patients with clopidogrel withdrawal because of the non-cardiac surgery
have the worst outcome among SES-implanted patients.The discontinuation of
clopidogrel in diabetic patients with EPC-coated stents doesn’t cause increase in
markers of inflammation compared to SES stents. Long lesion is the independent
predictors of restenosis after EPC stent implantation and the length of stented surface
correlates strongly with in-stent lumen diameter late loss.
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Background: Delayed healing, stent thrombosis, late-catch-up and neo-atherosclerosis
are unfavorable late-term outcomes associated in part with permanent polymers of
current drug-eluting stents (DES). The MiStent DES (Micell Technologies, Durham,
NC), designed for improved safety while maintaining strong efficacy, is characterized
by use of crystalline sirolimus, drug release at a controlled, linear rate, coating off the
stent in 45-60 days with full absorption of the polymer by 90 days and a thin strut
(64um) cobalt-chromium stent.
Methods: The DESSOLVE I FIH clinical trial is a prospective, single-arm study at 5
sites evaluating the MiStent DES for preliminary safety and efficacy. Patients with
discrete de novo lesions (2.5-3.5 mm diameter and ≤20 mm length) in native coronary
arteries were enrolled. Following the MiStent DES placement, patients were evenly
assigned to 3 groups for follow-up imaging (angiography, IVUS and OCT) at 4-months,
6-months or 8-months to determine in-stent late lumen loss (LLL), vessel healing, and
stent coverage. Clinical safety was conducted for all 30 patients at 8-months.
Results: The initial 10 patients evaluated at 4-months demonstrated an in-stent LLL
of 0.01 ± 0.12 mm assessed by core laboratory quantitative angiography. Imaging with
OCT demonstrated thin, homogenous coverage with high rates of stent strut coverage
(70% of the patients having >90% strut coverage and 90% having >80% strut coverage)
with a low rate of stent strut malapposition. The IVUS findings supported minimal
neointimal hyperplasia with a neointimal obstruction of 5.2%. Clinical outcomes and
angiographic, OCT and IVUS analyses at 4, 6 and 8-months for the entire study cohort
will be presented.
Conclusion: The MiStent DES, developed with a predictably absorbed polymer
encompassing a new morphology of sirolimus, may address current DES concerns
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